Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
about
Assessing the Immunogenicity of BiopharmaceuticalsImmunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesAntidrug Antibodies: B Cell Immunity Against TherapyRecent Advances in Application of Pharmacogenomics for BiotherapeuticsQuantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayA score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.How the immune system responds to therapeutic biological agents.Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
P2860
Q26751485-8BB93BBE-D6CA-4250-B13B-EC94FBD4F98FQ26766424-9783FD99-0FA7-4B87-AE72-B4BE6D99ABF0Q28082303-035EA271-4293-4667-B2A4-AA4710445CD9Q29247996-AF8ED048-AD78-4D0B-B86B-EF244416C9CAQ33745965-2F009A8C-9F84-4D21-9DAD-42428284C10AQ33860040-3B78E593-B83A-416E-9273-CE722FAAFC02Q37138974-989533DB-1E94-4F5F-BAF2-902874AE8E38Q38903708-F87060E0-7C16-4D88-A07F-D9938DF7FFDBQ38946563-70CDEB6A-0E97-4538-9EA0-9E4134A019D6Q40957502-4D83D728-B95F-4274-88A8-D22F05CB655FQ41882370-E3CB0733-F35F-4858-85BE-8087DCEE42DBQ45437801-FFDB0105-48CC-4DA7-8DDE-1D955D3F88AEQ50065301-34D481D5-78FA-460E-A411-4695869861AE
P2860
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@ast
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@en
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@nl
type
label
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@ast
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@en
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@nl
prefLabel
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@ast
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@en
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@nl
P2093
P2860
P50
P3181
P356
P1476
Standardizing terms, definitio ...... Initiative ABIRISK consortium
@en
P2093
A Fogdell-Hahn
A Hincelin-Mery
ABIRISK Consortium
B Maillère
C R Pedersen
D Mulleman
P2860
P304
P3181
P356
10.1111/CEI.12652
P407
P577
2015-07-02T00:00:00Z